SAN DIEGO, Sept. 4, 2020 /PRNewswire/ -- MEI Pharma, Inc.
(NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused
on advancing new therapies for cancer, today announced its
participation in the following upcoming virtual investor
conferences:
- Wells Fargo 2020 Virtual
Healthcare Conference on Thursday, September
10, 2020 at 2:40 p.m. ET
- H.C. Wainwright & Co. 22nd Annual Global
Investment Conference on Monday, September 14,
2020 at 12:00 p.m. ET
- Cantor Virtual Global Healthcare Conference on Thursday, September 17, 2020 at 4:00
p.m. ET
A live webcast of each presentation providing a company overview
and business update can be accessed on the Events &
Presentations page of the Investors section of MEI Pharma's website
at http://www.meipharma.com. An archived replay of
the webcast will be available on MEI Pharma's website for at
least 30 days after the live event concludes.
About MEI Pharma
MEI Pharma, Inc. (NASDAQ: MEIP) is a
late-stage pharmaceutical company focused on developing potential
new therapies for cancer. MEI Pharma's portfolio of drug candidates
contains four clinical-stage assets, including ME-401, currently in
an ongoing Phase 2 clinical trial which may support an accelerated
approval marketing application with the U.S. Food and Drug
Administration. Each of MEI Pharma's pipeline candidates leverages
a different mechanism of action with the objective of developing
therapeutic options that are: (1) differentiated, (2) address unmet
medical needs and (3) deliver improved benefit to patients either
as standalone treatments or in combination with other therapeutic
options. For more information, please
visit www.meipharma.com.
Forward-Looking Statements
Under U.S.
law, a new drug cannot be marketed until it has been investigated
in clinical studies and approved by the FDA as being safe and
effective for the intended use. Statements included in this press
release that are not historical in nature are "forward-looking
statements" within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995. You should be
aware that our actual results could differ materially from those
contained in the forward-looking statements, which are based on
management's current expectations and are subject to a number of
risks and uncertainties, including, but not limited to, our failure
to successfully commercialize our product candidates; costs and
delays in the development and or FDA approval, or the failure to
obtain such approval, of our product candidates; uncertainties or
differences in interpretation in clinical trial results; the impact
of the COVID-19 pandemic on our industry and individual companies,
including on our counterparties, the supply chain, the execution of
our clinical development programs, our access to financing and the
allocation of government resources; our inability to maintain or
enter into, and the risks resulting from our dependence upon,
collaboration or contractual arrangements necessary for the
development, manufacture, commercialization, marketing, sales and
distribution of any products; competitive factors; our inability to
protect our patents or proprietary rights and obtain necessary
rights to third party patents and intellectual property to operate
our business; our inability to operate our business without
infringing the patents and proprietary rights of others; general
economic conditions; the failure of any products to gain market
acceptance; our inability to obtain any additional required
financing; technological changes; government regulation; changes in
industry practice; and one-time events. We do not intend to update
any of these factors or to publicly announce the results of any
revisions to these forward-looking statements.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/mei-pharma-to-present-at-upcoming-investor-conferences-in-september-301124242.html
SOURCE MEI Pharma, Inc.